再鼎醫藥-SB(09688.HK)香港公開發售獲約3.43倍認購 預計9月28日掛牌上市
格隆匯 9 月 25日丨再鼎醫藥-SB(09688.HK)發佈公告,公司全球發售1056.405萬股股份,其中香港發售股份89.8萬股,國際發售股份966.605萬股,另有15%超額配股權;最終發售價已確定為每股股份562港元,每手買賣單位50股;預期股份將於2020年9月28日於聯交所主板掛牌上市。
香港公開發售項下初步可供認購的香港發售股份合共接獲10,349份有效申請,認購合共264.515萬股香港發售股份,相當於香港公開發售項下初步可供認購香港發售股份總數約3.43倍。國際發售項下初步提呈發售的發售股份獲大幅超額認購,相當於國際發售初步可供認購發售股份總數的約6.9倍。
按發售價每股562港元計算,估計集團將收取全球發售所得款項淨額約57.304億港元(假設超額配股權未獲行使)。其中,所得款項淨額約46.2%將分配至核心產品(包括約22.2%用於與核心產品相關的研發工作及約24.0%用於提升核心產品的商業化能力);約11.8%用於為進行中及計劃臨牀試驗以及管線中其他候選藥物(尤其是晚期候選藥物)的準備中註冊備案撥資;約25.0%用於探索新的全球授權及合作機會並引進具有臨牀驗證的潛在全球同類最佳╱同類首創資產,並與集團當前產品管線形成協同效應及與集團的專業知識保持一致;約7.0%用於持續投資及擴大集團的內部研發產品管線以及在全球招聘及培訓高端人才;及約10.0%用於為營運資金及其他一般企業用途撥資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.